The Motley Fool··Jonathan PoncianoMajor Investor Bet on Bright Minds Signals Confidence in BMB-101 Epilepsy Pipeline
B Group invests $5.43 million in Bright Minds Biosciences, signaling confidence in its epilepsy drug pipeline and well-funded development stage.
ADMADRUGinstitutional investmentbiotech investment